160088-53-9

Usage

Uses

Used in Pharmaceutical Industry:
N-(5-Chloro-4-methoxy-2-nitrophenyl)acetamide is used as a building block in the synthesis of various pharmaceutical drugs. Its unique structure and properties contribute to the development of new molecules with potential therapeutic properties.
Used in Research and Development:
In the field of research and development, N-(5-Chloro-4-methoxy-2-nitrophenyl)acetamide is utilized for the production of new molecules with potential therapeutic properties. Its unique structure and properties make it an important component in the discovery and development of novel drugs and pharmaceutical compounds.
Used in Medicine and Biotechnology:
N-(5-Chloro-4-methoxy-2-nitrophenyl)acetamide has potential applications in medicine and biotechnology due to its unique structure and properties. It can be used in the development of new drugs and therapeutic agents, contributing to advancements in medical treatments and biotechnological applications.

Upstream product

• 7073-42-9 N-(3-chloro-4-methoxyphenyl)acetamide 
• 5345-54-0 3-chloro-4-methoxyaniline 
• 4920-79-0 2-chloro-4-nitroanisole 

Downstream Products

• 160088-54-0 5-Chloro-4-methoxy-2-nitroaniline 
• 1026083-32-8 1-Azido-5-chloro-4-methoxy-2-nitro-benzene 
• 38608-06-9 5-chloro-4-methoxy-o-phenylenediamine 
• 107095-81-8 C₁₅H₁₃FN₂O₅ 
• 1361026-06-3 C₁₅H₁₃ClN₂O₅ 
• 1361026-04-1 C₁₅H₁₃BrN₂O₅ 
• 1361026-00-7 4-acetamino-2-(3-fluorophenyloxy)-5-nitro-anisole 
• 1361025-99-1 C₁₅H₁₃FN₂O₅ 
• 1361026-05-2 C₁₅H₁₃ClN₂O₅ 
• 1361026-03-0 C₁₅H₁₃BrN₂O₅ 
• 198130-51-7 2-nitro-4-methoxy-5-(3,4-dichlorophenoxy)acetanilide 
• 1361026-02-9 C₁₅H₁₂F₂N₂O₅ 
• 98081-50-6 4-acetamino-5-nitro-2-(3-trifluoromethylphenyloxy)anisole 
• 1361026-01-8 C₁₅H₁₂F₂N₂O₅ 

Relevant academic research and scientific papers

PHOSPHOGLYCERATE KINASE INHIBITORS

Disclosed are compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined in the description. Disclosed are also the methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as phosphoglycerate kinase.

Positive allosteric modulators of the nicotinic acetylcholine receptor

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.

Hypoxia-Selective Agents Derived from Quinoxaline 1,4-Di-N-oxides

Hypoxic cells, which are a common feature of solid tumors, but not normal tissues, are resistant to both anticancer drugs and radiation therapy.Thus the identification of drugs with selective toxicity toward hypoxic cells is an important objective in anticancer chemotherapy.The benzotriazine di-N-oxide (SR 4233, Tirapazamine) has been shown to be an efficient and selective cytotoxin for hypoxic cells.Since the bioreductive activation of Tirapazamine is thought to be due to the presence of the 1,4-di-N-oxide moiety, a series of 3-aminoquinoxaline-2-carbonitrile 1,4-di-N-oxides with a range of electron-donating and -withdrawing substituents in the 6- and /or 7- positions has been synthesized and evaluated for toxicity to hypoxic cells.Electrochemical studies of the quinoxaline di-N-oxides and Tirapazamine showed that as the electron-withdrawing nature of the 6(7)-substituent increases, the reduction potential becomes more positive and the compound is more readily reduced.Apart from the unsubstituted 6a and the 6,7-dimethyl derivative 6c, the quinoxaline di-N-oxide have reduction potentials significantly more positive than Tirapazamine (Epc -0.90 V).The most potent cytotoxins to cells in culture were the 6,7-dichloro and 6,7-difluoro derivatives 6i and 6l, which were 30-fold more potent than Tirapazamine.The 6(7)-fluoro and 6(7)-chloro compounds, 6e and 6h, showed the greatest hypoxia selectivity.Four of the compounds, 6e, 6f, 6h and 6i, killed the inner cells of multicellular tumor spheroids in vitro.In vivo Balb/c mice tolerated a dose of these four compounds twice the size of that of Tirapazamine.This study demonstrates that quinoxaline 1,4-di-N-oxides could provide useful hypoxia-selective therapeutic agents.

Polyaza Heterocycles. Part 2. Nucleophilic Substitution of Halogens in Halogenoquinoxalinocinnolines

10-Chloroquinoxalinocinnoline readily undergoes methoxydechlorination when treated with sodium methoxide.The 1-, 2-, 3-, 4- and 9-chloro isomers are unreactive towards this reagent, but the 9,10-dichloro derivative undergoes substitution of both chlorines (the 10-position being much the more reactive).The 9- and 10-bromo analogues are both unreactive towards sodium methoxide, but the 9- and 10-fluoro analogues are both highly reactive, to the extent that it has not been possible even to isolate the 10-fluoro compound.Routes to 9- and 10-piperidinoquinoxalinocinnolines are described.